摘要
目的 :评价靶向性非病毒载体系统介导的 p2 1WAF1对人喉癌基因治疗的可行性和有效性。方法 :利用组建的表皮生长因子受体 (EGF R)介导的多肽基因导入系统与p2 1WAF1基因构成基因载体复元物 ,分别体外转染人喉癌Hep 2细胞 ,通过荧光显微镜观察和通过转染喉癌细胞生长曲线及流式细胞仪检测等方法观察新的受体介导多肽基因导入系统对外源基因的导入和导入后对人喉癌细胞的抑制作用。结果 :荧光显微镜观察到标记基因的表达产物绿色荧光蛋白 ,转染后 4 8h呈弱阳性 ,72h呈强阳性 ;p2 1WAF1基因转染后喉癌细胞生长受到明显抑制 ,第 4天抑制率为 79% ;流式细胞仪检测到p2 1WAF1转染的Hep 2细胞发生了明显的凋亡。结论 :EGF R介导的多肽基因导入系统可靶向性地将治疗基因导入Hep 2人喉癌细胞 ,p2 1WAF1基因可明显抑制Hep 2细胞的生长并有效诱导基因凋亡。
Objective:To evaluate the efficiency of EGF-R targeted polypeptide gene delivery system and inhibitory effect of p21 WAF1 on squamous cell carcinoma of larynx.Method:The EGF-Rtargeting polypeptide gene delivery system was constructed and a therapeutic gene of p21 WAF1 were transfected into Hep-2 cells with the new gene delivery system.The growth curve of transfected Hep-2 cells and flow cytometric analysis were applied to assess the transferring and expression of exogenous genes and inhibitory effect on Hep-2 cells.Result:With the transferring of p21 WAF1 gene, the growth of Hep-2 cells was inhibited significantly by 79%, and the apoptosis was observed by means of flow cytometric analysis.Conclusion:EGF-R targeting polypeptide gene delivery system could transfer the therapeutic gene into targeted EGF-R expressing Hep-2 cells and the expression of p21 WAF1 could inhibit the growth of Hep-2 cells and induced the cells to apoptosis.
出处
《临床耳鼻咽喉科杂志》
CSCD
北大核心
2004年第9期555-557,i001,共4页
Journal of Clinical Otorhinolaryngology
基金
卫生部基金资助项目 (No :982 2 8)
